Effects of MAFLD defined by fatty liver index or ultrasonography on kidney function decline in the general population.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 Sep 2024
Historique:
received: 31 05 2024
accepted: 09 09 2024
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 11 9 2024
Statut: epublish

Résumé

This study aimed to investigate whether metabolic dysfunction-associated fatty liver disease (MAFLD) defined by the fatty liver index (FLI) affects the decline in kidney function and whether this relationship is still observed in MAFLD defined by ultrasonography (USG). A retrospective cohort study was conducted using de-identified data from participants who received health checkups at Samsung Changwon Hospital between 2002 and 2018. The primary and secondary exposures were the presence of FLI- and USG-defined MAFLD, respectively. The primary outcome was 5-years slope of eGFR. The secondary outcome was a rapid decline in kidney function, defined as a 5-years slope of estimated glomerular filtration rate (eGFR) of less than - 3 mL/min/1.73 m

Identifiants

pubmed: 39261554
doi: 10.1038/s41598-024-72482-0
pii: 10.1038/s41598-024-72482-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21189

Informations de copyright

© 2024. The Author(s).

Références

Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73, 202–209. https://doi.org/10.1016/j.jhep.2020.03.039 (2020).
doi: 10.1016/j.jhep.2020.03.039 pubmed: 32278004
Yuan, Q. et al. Prevalence and risk factors of metabolic-associated fatty liver disease among 73,566 individuals in Beijing, China. Int. J. Environ. Res. Public Health https://doi.org/10.3390/ijerph19042096 (2022).
doi: 10.3390/ijerph19042096 pubmed: 36612889 pmcid: 9819955
Wong, V. W. et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin. Gastroenterol. Hepatol. 19, 2161-2171e2165. https://doi.org/10.1016/j.cgh.2020.10.046 (2021).
doi: 10.1016/j.cgh.2020.10.046 pubmed: 33137486
Kwon, S. Y. et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci. Rep. 13, 1796. https://doi.org/10.1038/s41598-023-27762-6 (2023).
doi: 10.1038/s41598-023-27762-6 pubmed: 36720976 pmcid: 9889784
Sun, D. Q. et al. MAFLD and risk of CKD. Metabolism 115, 154433. https://doi.org/10.1016/j.metabol.2020.154433 (2021).
doi: 10.1016/j.metabol.2020.154433 pubmed: 33212070
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G. & Barbui, C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J. Hepatol. 65, 589–600. https://doi.org/10.1016/j.jhep.2016.05.013 (2016).
doi: 10.1016/j.jhep.2016.05.013 pubmed: 27212244
Mantovani, A. et al. MAFLD and CKD: An updated narrative review. Int. J. Mol. Sci. https://doi.org/10.3390/ijms23137007 (2022).
doi: 10.3390/ijms23137007 pubmed: 36362108 pmcid: 9654863
Nalbantoglu, I. L. & Brunt, E. M. Role of liver biopsy in nonalcoholic fatty liver disease. World J. Gastroenterol. 20, 9026–9037. https://doi.org/10.3748/wjg.v20.i27.9026 (2014).
doi: 10.3748/wjg.v20.i27.9026 pubmed: 25083076 pmcid: 4112884
Tsai, E. & Lee, T. P. Diagnosis and evaluation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, including noninvasive biomarkers and transient elastography. Clin. Liver Dis. 22, 73–92. https://doi.org/10.1016/j.cld.2017.08.004 (2018).
doi: 10.1016/j.cld.2017.08.004 pubmed: 29128062
Liao, Y. Y. et al. Multifeature analysis of an ultrasound quantitative diagnostic index for classifying nonalcoholic fatty liver disease. Sci. Rep. 6, 35083. https://doi.org/10.1038/srep35083 (2016).
doi: 10.1038/srep35083 pubmed: 27734972 pmcid: 5062088
Bedogni, G. et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6, 33. https://doi.org/10.1186/1471-230X-6-33 (2006).
doi: 10.1186/1471-230X-6-33 pubmed: 17081293 pmcid: 1636651
Cho, E. J. et al. Fatty liver index for predicting nonalcoholic fatty liver disease in an asymptomatic Korean population. Diagnostics https://doi.org/10.3390/diagnostics11122233 (2021).
doi: 10.3390/diagnostics11122233 pubmed: 35054251 pmcid: 8774861
Huang, X. et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine 94, e1682. https://doi.org/10.1097/MD.0000000000001682 (2015).
doi: 10.1097/MD.0000000000001682 pubmed: 26448014 pmcid: 4616754
Jha, V. et al. Chronic kidney disease: global dimension and perspectives. Lancet 382, 260–272. https://doi.org/10.1016/S0140-6736(13)60687-X (2013).
doi: 10.1016/S0140-6736(13)60687-X pubmed: 23727169
Zhou, X. D. et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc. Diabetol. 21, 270. https://doi.org/10.1186/s12933-022-01697-0 (2022).
doi: 10.1186/s12933-022-01697-0 pubmed: 36463192 pmcid: 9719631
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 (2009).
doi: 10.7326/0003-4819-150-9-200905050-00006 pubmed: 19414839 pmcid: 2763564
Guajardo-Salinas, G. E. & Hilmy, A. Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese Hispano-American patients undergoing gastric bypass. Obes. Surg. 20, 1647–1653. https://doi.org/10.1007/s11695-009-0027-0 (2010).
doi: 10.1007/s11695-009-0027-0 pubmed: 19957049
Perez, N. E. et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: A retrospective observational study. J. Clin. Gastroenterol. 41, 624–629. https://doi.org/10.1097/01.mcg.0000225680.45088.01 (2007).
doi: 10.1097/01.mcg.0000225680.45088.01 pubmed: 17577120
Mishra, P. & Younossi, Z. M. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am. J. Gastroenterol. 102, 2716–2717. https://doi.org/10.1111/j.1572-0241.2007.01520.x (2007).
doi: 10.1111/j.1572-0241.2007.01520.x pubmed: 18042105
Khov, N., Sharma, A. & Riley, T. R. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J. Gastroenterol. 20, 6821–6825. https://doi.org/10.3748/wjg.v20.i22.6821 (2014).
doi: 10.3748/wjg.v20.i22.6821 pubmed: 24944472 pmcid: 4051921
Ryu, S., Chang, Y., Kim, D. I., Kim, W. S. & Suh, B. S. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin. Chem. 53, 71–77. https://doi.org/10.1373/clinchem.2006.078980 (2007).
doi: 10.1373/clinchem.2006.078980 pubmed: 17110470
Pan, Z., Alqahtani, S. A. & Eslam, M. MAFLD and chronic kidney disease: two sides of the same coin?. Hepatol. Int. 17, 519–521. https://doi.org/10.1007/s12072-023-10526-9 (2023).
doi: 10.1007/s12072-023-10526-9 pubmed: 37069420
Kadatane, S. P., Satariano, M., Massey, M., Mongan, K. & Raina, R. The Role of Inflammation in CKD. Cells https://doi.org/10.3390/cells12121581 (2023).
doi: 10.3390/cells12121581 pubmed: 37371050 pmcid: 10296717
Popolo, A., Autore, G., Pinto, A. & Marzocco, S. Oxidative stress in patients with cardiovascular disease and chronic renal failure. Free Radic. Res. 47, 346–356. https://doi.org/10.3109/10715762.2013.779373 (2013).
doi: 10.3109/10715762.2013.779373 pubmed: 23438723
Raj, D., Tomar, B., Lahiri, A. & Mulay, S. R. The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease. Pharmacol. Res. 152, 104617. https://doi.org/10.1016/j.phrs.2019.104617 (2020).
doi: 10.1016/j.phrs.2019.104617 pubmed: 31881272
Chen, W. et al. Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transpl. 24, 1205–1212. https://doi.org/10.1093/ndt/gfn604 (2009).
doi: 10.1093/ndt/gfn604
Ingsathit, A. et al. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transpl. 25, 1567–1575. https://doi.org/10.1093/ndt/gfp669 (2010).
doi: 10.1093/ndt/gfp669

Auteurs

Yu-Ji Lee (YJ)

Division of Nephrology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon, 51353, Republic of Korea. yuji.lee@samsung.com.

Kwang Min Kim (KM)

Division of Gastroenterology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.

Nak Gyeong Ko (NG)

Department of Research and Support, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.

Mihyeon Jin (M)

Department of Research and Support, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.

Jin Hee Na (JH)

Division of Nephrology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon, 51353, Republic of Korea.

In Ho Park (IH)

Division of Nephrology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, 158, Paryong-ro, Masanhoewon-gu, Changwon, 51353, Republic of Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH